A soccer ball-shaped, nanoparticle-sized vaccine delivery platform called Q-Beta might hold the key to unlocking treatments for any number of viruses and diseases — from cancers to infections and even opioid addiction — thanks to the work of a research team that got its start at Michigan State University.

This groundbreaking research is currently being done by Xuefei Huang, a professor in MSU’s Departments of Biomedical Engineering and Chemistry, along with a team of collaborators to develop the East Lansing-based startup company Iaso Therapeutics.

After decades of laboratory research and development, Huang recognized the need to bridge the gap between translating his discoveries in MSU labs into products that make life better in the real world.

With assistance from the combined efforts of MSU Technologies and the MSU Research Foundation, DHuang launched Iaso Therapeutics to continue the landmark research into the Q-Beta antigen delivery platform, a product that has the opportunity to save thousands of lives.

To read more, visit innovationcenter.msu.edu.